Do Hematological Parameters Have a Significant Role in Predicting the Results of Prostate Biopsies?

Abstract

Objective: To assess the predictive role of hematological parameters on the results of prostate biopsies. Method: We evaluated patients who underwent ultrasound-guided prostate biopsies between January 2014 and April 2016. The patients were divided into two groups according to their histopathological results: as patients with and without established diagnosis of prostate cancer. White blood cell, neutrophil, lymphocyte, platelet counts, hemoglobin level, hematocrit, red cell distribution width, mean platelet volume, platelet distribution width and plateletcrit were analyzed before biopsy. Additionally, neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios were calculated. These parameters were compared between the two groups and statistically analyzed. Results: Prostate cancer was detected in 38 (30.25%) patients, and benign conditions (prostatic hyperplasia or chronic prostatitis) were detected in 88 (69.85%) patients. There was no statistically significant difference between the patients with prostate cancer and patients with benign conditions according to the white blood cell, neutrophil, lymphocyte, platelet counts, hemoglobin level, hematocrit, red cell distribution width, mean platelet volume and platelet distribution width and plateletcrit. Additionally, there were no statistically significant differences between the groups regarding the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Conclusion: Hematological parameters do not play a significant role in predicting prostate biopsy results. More sophisticated studies are needed to further evaluate this issue.